iReact - Intelligent Multimodal Digital Ophthalmic Measuring Device with enabled AI Tele-Ophthalmology

这项英国/新加坡的研发合作结合了专业医疗器械设计师、人机工程师、软件/电子工程师和眼科专家临床医生的团队，开发了一种负担得起、获得专利、可靠和易于使用的设备-iReact智能多模式数字眼科测量设备，支持AI远程眼科。保护视力和及早发现眼睛和其他疾病是通过一系列描述良好的测试来完成的。假阳性转诊、现有的等待名单、Covid恶化和需要长期眼睛护理的老龄化人口正在增长，而没有相应数量的眼科医生和临床资源来满足这种需求-容量压力增加了患者不良结果的风险。这就产生了对创新眼科技术的需求，以减少需求，并快速识别和监测最需要的患者的眼病。iReact技术结合了眼睛成像评估和测试，将其带给英国、新加坡和全球市场的数百万患者。除了明显的健康和残疾福利的减少外，这项技术还将为卫生和社会护理服务带来显着的成本节约。眼科的市场和投资回报是全球范围的。眼科目前只在专业眼科诊所进行测量，最终将通过大街上的配镜商和初级保健使用复杂但操作简单的设备来实现。规模化部署的iReact减少眼科门诊预约，通过减少不必要的转介和实现社区/初级保健眼科测试，每年将为NHS节省数百万GB。眼科是NHS最繁忙的专业之一，每年提供超过900万次的门诊预约，费用超过10亿GB/年。随着人口老龄化，青光眼等与年龄相关的视力受损疾病的患病率和治疗成本大幅增加。然而，如果及早诊断并仔细监测，相当大比例的失明和失明是可以预防的。如果不加以控制，失明和失明会给个人和国家造成相当大的健康负担。据估计，英国成年人的失明每年会造成280亿英镑的经济损失。NHS的长期计划认识到了这些需求，并支持社区和初级保健对眼睛护理服务的需求，这有助于减少不必要的转诊到眼科专科诊所。在规模上提供，通过综合眼科护理路径联系起来，侧重于早期发现、有效转介以及迅速获得和治疗，帮助减少不必要的视力损失。

This UK/Singapore R&D collaboration combines a team of specialist Medical Device Designers, Human-factors, Software/Electronic Engineers, Eye Specialist clinicians to develop an affordable, patented, reliable, and easy-to-use device, the iReact Intelligent Multimodal Digital Ophthalmic Measuring Device with enabled AI Tele-Ophthalmology.Eye tests are a ubiquitous part of modern healthcare. Preservation of sight and the early detection of both eye and other diseases are accomplished by a range of well described tests.False-positive referrals, existing waiting-lists, Covid-exacerbation and ageing populations requiring long-term eye-care is growing without the commensurate number of Ophthalmologists and Clinical resources to meet this demand-pressure on capacity - increasing risk of adverse-outcomes-for-patients.This creates the need for an innovative ophthalmic-technology to reduce-demand and rapidly identify and monitor eye-disease in patients who need it most.iReact technology combines eye imaging assessment and testing bringing it to millions of patients in the UK, Singapore and Global market. Apart from the obvious health and reduction in disability benefits this technology will also bring significant cost savings to health and social care services. The market, and return on investments, is worldwide.Measurements currently only made in specialist eye clinics, will be eventually be available through high street opticians and Primary Care using a sophisticated but simple to operate device.Reducing eye-care outpatient appointments with the iReact, deployed at scale, will save the NHS £millions/year by reducing unnecessary referrals and enabling community/primary care-eye-testing.Ophthalmology is one of the busiest specialties in the NHS, providing over 9 million outpatient appointments per year costing over £1Billion/year.Age-related sight-impairing diseases such as Glaucoma have dramatically increased in prevalence and in treatment costs as the population ages. However, a significant proportion of sight-loss and blindness is preventable if diagnosed early and with careful monitoring. Unchecked, sight-loss and blindness cause a considerable health burden on individuals and the state. Its estimated sight-loss in adults costs the UK economy £28 billion a year.The NHS Long Term plan recognises these demands and supports the need for eye-care services at Community and Primary care that can help reduce unnecessary referrals to specialist eye clinics. Provided at scale, linked via Integrated-Eye-Care-Pathways focusing on early detection, effective referrals and prompt access and treatment helping to reduce unnecessary sight-loss.